Director, Regulatory Affairs
lyellimmunopharma
Seattle, Washington, United States; South San Francisco, California, United States · Seattle · United States
Posted Aug 21, 2026
- Other
- Regulatory Affairs
lyellimmunopharma
Seattle, Washington, United States; South San Francisco, California, United States · Seattle · United States
Posted Aug 21, 2026
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.
This role can be based out of either our Seattle, WA or South San Francisco, CA offices.
The Director of Regulatory Affairs/Global Regulatory Lead (GRL) will be focusing on the development of cutting-edge CAR-T cell therapies in oncology.
As the GRL, you will define, develop, and execute the global regulatory strategy for assigned CAR-T programs from early clinical development through licensure (BLA/MAA) and lifecycle management. You will serve as the primary regulatory representative to global health authorities (FDA, EMA, etc.), ensuring alignment with business objectives and driving innovative approaches to accelerate the development of transformative therapies for patients.
Global Regulatory Strategy & Leadership
Health Authority Interactions
Cross-Functional Collaboration
Regulatory Intelligence
Bachelor’s degree in Life Sciences required. Advanced degree (PhD, PharmD, or MD) is strongly preferred.
Experience: A minimum of 15+ years in the biopharmaceutical industry, with at least 8 years of direct Regulatory Affairs experience.
Modalities: Substantial experience in cell and gene therapy, specifically with CAR-T or T-cell engaging modalities.
Submissions: Proven track record of leading major submissions (IND/CTA) and experience in BLA/MAA preparation.
HA Interactions: Proven ability to interact effectively and negotiate with regulatory authorities.
Desired Skills: